Results 21 to 30 of about 33,833 (238)
Future Journal of Pharmaceutical Sciences, 2021 Background Tuberculosis is an infection that has high mortality rate in human as well as in animals if it remains unattained for long time. Scientists are always desirous to discover new molecules against Mycobacterium tuberculosis; one of them is ...
S. J. Rajput, P. J. Vanavi
doaj +1 more source
Prolonged use of bedaquiline in the treatment for MDR-TB in a child
IDCases, 2021 Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months.
Marina F. Gubkina +3 more
doaj +1 more source
In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria [PDF]
, 2017 Bedaquiline (BDQ) has been proven to be effective in the treatment of multidrug-resistant tuberculosis. We hypothesized that BDQ could be a potential agent to treat nontuberculous mycobacterial (NTM) infection. The objective of this study was to evaluate
Aguilar-Ayala, Diana +7 more
core +2 more sources
International Journal of Infectious Diseases, 2018 The use of bedaquiline to treat patients with multidrug-resistant tuberculosis (MDR-TB) and end-stage renal disease (ESRD) may raise safety concerns. Currently, no clinical information is available on the use of bedaquiline to treat MDR-TB patients with ...
Seyeon Park +3 more
doaj +1 more source
A Novel Diarylquinoline for Multidrug-Resistant Tuberculosis [PDF]
, 2014 Objective: To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosage, and administration of bedaquiline, a novel oral diarylquinoline antimycobacterial agent approved by the Food and Drug ...
Chahine, Elias B. +2 more
core +1 more source
Microbiology Spectrum, 2023 With the application of bedaquiline (Bdq), the success rate of multidrug-resistant tuberculosis (MDR-TB) treatment has been significantly improved; however, the cardiac safety of the patients during treatment cannot be ignored. Hence, this study compared
Rong Li +6 more
doaj +1 more source
PLoS Medicine, 2016 BackgroundNew drugs for the treatment of tuberculosis (TB) are becoming available for the first time in over 40 y. Optimal strategies for introducing these drugs have not yet been established.
Amber Kunkel +2 more
doaj +1 more source
PRS45 Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients [PDF]
, 2011 Fitxes dels ...
Punekar, Y.S. +3 more
core +1 more source
Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study
medRxivBackground: Rising prevalence of bedaquiline resistance undermines benefits from this life-saving drug for rifampicin-resistant tuberculosis (RR-TB). Despite increasing awareness, patient-level outcomes for bedaquiline-resistant TB have not been well ...
Lindokuhle Mdlenyani +7 more
semanticscholar +2 more sources
The Lancet Microbe, 2023 Summary Background Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up. People at risk of weak tuberculosis drug regimens are a priority for novel drug access despite the potential source of Mycobacterium tuberculosis-resistant ...
B. Derendinger +23 more
semanticscholar +1 more source